These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16288296)

  • 1. AKT crystal structure and AKT-specific inhibitors.
    Kumar CC; Madison V
    Oncogene; 2005 Nov; 24(50):7493-501. PubMed ID: 16288296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
    Harris TK
    IUBMB Life; 2003 Mar; 55(3):117-26. PubMed ID: 12822887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
    Li Q; Li T; Zhu GD; Gong J; Claibone A; Dalton C; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Bauch JL; Marsh KC; Bouska JJ; Arries S; De Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1679-85. PubMed ID: 16403626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
    Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
    J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
    Lin X; Murray JM; Rico AC; Wang MX; Chu DT; Zhou Y; Del Rosario M; Kaufman S; Ma S; Fang E; Crawford K; Jefferson AB
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4163-8. PubMed ID: 16765046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
    Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
    J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors.
    Siu T; Liang J; Arruda J; Li Y; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4186-90. PubMed ID: 18539456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
    Fujita N
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
    Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
    J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR).
    Hubbard RD; Wilsbacher JL
    ChemMedChem; 2007 Jan; 2(1):41-6. PubMed ID: 17089440
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
    Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
    Zhu GD; Gong J; Gandhi VB; Woods K; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Stoll VS; Mamo M; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem; 2007 Mar; 15(6):2441-52. PubMed ID: 17258463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity.
    Zhang Y; Shen X
    Clin Cancer Res; 2007 May; 13(10):2855-64. PubMed ID: 17504983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
    Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Akt in cancer therapy.
    LoPiccolo J; Granville CA; Gills JJ; Dennis PA
    Anticancer Drugs; 2007 Sep; 18(8):861-74. PubMed ID: 17667591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold.
    Hernández-Campos A; Velázquez-Martínez I; Castillo R; López-Vallejo F; Jia P; Yu Y; Giulianotti MA; Medina-Franco JL
    Chem Biol Drug Des; 2010 Sep; 76(3):269-76. PubMed ID: 20572809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
    Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationship studies of peptidomimetic PKB/Akt inhibitors: the significance of backbone interactions.
    Tal-Gan Y; Freeman NS; Klein S; Levitzki A; Gilon C
    Bioorg Med Chem; 2010 Apr; 18(8):2976-85. PubMed ID: 20347317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
    Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
    Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.